Shock wave device aims to clear blocked leg arteries without surgery
NCT ID NCT06457685
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device called Pulse IVL that uses sound waves to break up hard calcium deposits in leg arteries, helping blood flow better in people with peripheral artery disease (PAD). About 115 adults with moderate to severe PAD will receive the treatment. The goal is to see if the device is safe and effective at opening blocked vessels, but it is not a cure and ongoing management may still be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
115 people
The number who actually took part.
- Started
-
Sep 2024
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
General Inclusion Criteria Candidates will be included in the study only if all of the following conditions are met: 1. Able and willing to comply with all assessments in the study. 2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate, and has signed the approved consent form. 3. \>18 years old 4. Rutherford Clinical Category 2, 3, or 4 of the target limb 5. Resting ankle-brachial index (ABI) of ≤0.90, or ≤0.75 after exercise, of the target leg OR ≥70% stenosis by prior imaging (CT/MR angiogram, DUS). 6. Subjects has de novo lesions who are felt to have indication for peripheral angiography and endovascular intervention by the investigator per their standard of care. 7. Estimated life expectancy \>1 year, in the opinion of the investigator at the time of screening. Angiographic Inclusion Criteria Candidates will be included in the study only if all of the following intraoperative conditions are met: 1. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline. 2. Target lesion that is located in a native de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to 2 cm above the bifurcation, or trifurcation, of the tibial artery). 3. Target lesion reference vessel diameter is between 4.0 mm and 6.5 mm by visual estimate. 4. Target zone is ≤ 150 mm in total contiguous treatable length. Target lesion can be all or part of the 150 mm zone. 5. Target lesion is ≥70% stenosis via visual estimate. 6. Subject has at least one patent tibial vessel on the target leg with runoff to the ankle (not supported by collateral circulation.) Tibial vessel patency is defined as no stenosis \>50%. 7. Ability to pass the guidewire across the atherosclerotic lesion, without the use of re-entry devices. 8. No evidence of aneurysm or acute or chronic thrombus in target vessel. 9. Calcification is at least moderate. (Presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending ≥ 50% the length of the lesion.) General Exclusion Criteria Candidates will be excluded from the study if any of the following conditions are present: 1. Rutherford Clinical Category 0, 1, 5 and 6. 2. Active infection in the target leg. 3. Planned major amputation of the target leg (transmetatarsal or higher). 4. History of prior endovascular or surgical procedure on the target limb within the past 30 days. 5. Retrograde pedal/tibial access for intervention. 6. Known coagulopathy or has a bleeding diathesis, thrombocytopenia with platelet count \< 100,000/microliter, or International Normalized Ratio (INR) \>1.5. 7. Lesion in contralateral limb requiring intervention within the next 30 days. 8. Subject contraindicated for antiplatelet, anticoagulant, or thrombolytic therapy. 9. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated. 10. Known allergy to any Pulse IVL product materials. 11. Clinically significant myocardial infarction within 60 days prior to enrollment. 12. History of stroke within 60 days prior to enrollment. 13. History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to enrollment. 14. History of thrombolytic therapy within two weeks of enrollment. 15. Acute or chronic renal disease (e.g., as measured by a serum creatinine of \>2.5 mg/dL or \>220 umol/L), or on dialysis. 16. Pregnant or nursing. 17. Participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint. 18. Other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment. Angiographic Exclusion Criteria Candidates will be excluded from the study if any of the following intraoperative conditions are met: 1. The use of chronic total occlusion (CTO) re-entry devices. 2. Chronic Total Occlusion (CTO) greater than 40mm in length. 3. Any in-stent restenosis within the target zone. 4. Lesions within 10 mm of ostium of the SFA. 5. Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon). 6. Target lesion within surgical bypass grafts. 7. Subject has significant stenosis (\>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated without complications. 8. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to the target lesion at the time of the enrollment/index procedure.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Peripheral arterial disease(PAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Endovascular Physicians
West Orange, New Jersey, 07052, United States
-
Advanced Heart and Vein Center
Thornton, Colorado, 80023, United States
-
Arkansas Heart Hospital
Little Rock, Arkansas, 72022, United States
-
Ascension Seton
Austin, Texas, 78723, United States
-
Columbia University and New York Presbyterian Hospital (NYPH)
New York, New York, 10032, United States
-
Mainline Health Lankenau
Bryn Mawr, Pennsylvania, 19010, United States
-
Mercy Hospital South
St Louis, Missouri, 63128, United States
-
Midwest Cardiovascular Research Foundation
Davenport, Iowa, 52802, United States
-
Mount Sinai
New York, New York, 10029, United States
-
NC Heart and Vascular Research
Raleigh, North Carolina, 27607, United States
-
NYU Langone
New York, New York, 10016, United States
-
OhioHealth Riverside
Columbus, Ohio, 43214, United States
-
Piedmont Heart Institute
Atlanta, Georgia, 30309, United States
-
The Christ Hospital
Cincinnati, Ohio, 45219, United States
-
The Heart Hospital Baylor Plano
Plano, Texas, 75093, United States
-
The Miriam Hospital - Brown University Health Partner
Providence, Rhode Island, 02906, United States
-
UPMC Pinnacle
Mechanicsburg, Pennsylvania, 17050, United States
-
University Hospital- Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Vascular and Interventional Specialists of Orange County
Orange, California, 92868, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI plus ultrasound could catch heart and lung decline before it turns critical
- Can a flash of light reveal how well angioplasty restores blood flow in diabetic feet?
- Can a simple walk predict vascular disease? new study investigates
- New ultrasound technique aims to save limbs in artery disease patients
- Tailored blood thinners could save limbs in PAD patients
- Blood test may prevent clots after leg surgery